Drugs / F-18 florbetapir
F-18 florbetapir
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03040427 | Jan 2017 → Aug 2019 | amyloidosis | The Cleveland Clinic | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01683825 | Mar 2013 → Oct 2018 | amyloidosis | Brigham and Women's Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F-18 florbetapir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01683825 ↗ |
| Known as | F-18 labeled Florbetapir (Trade Name: Amyvid) | “F-18 labeled Florbetapir (Trade Name: Amyvid)” NCT01683825 ↗ |
| Known as | Florbetapir F-18 | “Florbetapir F-18 has been well tolerated in studies of more than 2000 human subjects.” NCT01683825 ↗ |
| Modality | Diagnostic / imaging agent | “Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid).” NCT03040427 ↗ |